<DOC>
	<DOCNO>NCT01070524</DOCNO>
	<brief_summary>Cross-over study evaluate effect trough FEV1 4 week treatment CHF5188 pMDI qd adult patient persistent asthma</brief_summary>
	<brief_title>Cross-over Study Evaluate Effect Trough Forced Expiratory Volume One Second ( FEV1 ) After 4 Weeks Treatment With CHF 5188 pMDI qd Adult Patients With Persistent Asthma</brief_title>
	<detailed_description>A randomised , double-blind , multinational , multicentre , active-controlled , 3-way cross-over study evaluate effect trough FEV1 4 week treatment CHF5188 pMDI qd adult patient moderate severe persistent asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Moderate severe asthma partly control ICS ICS/LABA FEV1 ≥ 60 % ≤ 90 % predicted patient normal value Diagnosis COPD History current evidence significant cardiovascular disease Uncontrolled concomitant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>